TCBP Responds to False Social Media Claim
TC BioPharm (NASDAQ: TCBP) has officially refuted false social media claims regarding its potential delisting from Nasdaq. The company, which develops allogeneic gamma-delta T cell therapies, addressed rumors from a now-deleted social media post that incorrectly stated the company had filed an 8-K Notice to delist. TC BioPharm confirmed it remains fully compliant with all Nasdaq listing requirements and will continue trading on the exchange. The company indicated it will take action to defend against such misleading claims aimed at creating negative market dynamics.
TC BioPharm (NASDAQ: TCBP) ha ufficialmente smentito false affermazioni sui social media riguardo a un possibile delisting da Nasdaq. L'azienda, che sviluppa terapie con cellule T gamma-delta allogeniche, ha affrontato le voci di un post sui social ora rimosso che affermava erroneamente che l'azienda avesse presentato un 8-K Notice per il delisting. TC BioPharm ha confermato di essere pienamente conforme a tutti i requisiti di quotazione di Nasdaq e continuerà a negoziare sulla borsa. L'azienda ha indicato che prenderà provvedimenti per difendersi da tali affermazioni fuorvianti mirate a creare dinamiche di mercato negative.
TC BioPharm (NASDAQ: TCBP) ha desmentido oficialmente las falsas afirmaciones en redes sociales sobre su posible exclusión de Nasdaq. La compañía, que desarrolla terapias con células T gamma-delta alogénicas, abordó los rumores de una publicación en redes sociales que ya ha sido eliminada y que afirmaba incorrectamente que la empresa había presentado un 8-K Notice para la exclusión. TC BioPharm confirmó que sigue cumpliendo plenamente con todos los requisitos de cotización de Nasdaq y continuará cotizando en el mercado. La compañía indicó que tomará medidas para defenderse contra tales afirmaciones engañosas destinadas a crear dinámicas de mercado negativas.
TC BioPharm (NASDAQ: TCBP)는 나스닥에서의 상장 폐지 가능성에 대한 잘못된 소셜 미디어 주장을 공식적으로 부인했습니다. 이 회사는 알로겐 계열 감마-델타 T 세포 요법을 개발하며, 현재 삭제된 소셜 미디어 게시물에서 회사가 상장 폐지를 위한 8-K 통지를 제출했다고 잘못 주장한 루머를 다뤘습니다. TC BioPharm은 나스닥 상장 요구사항을 완전히 준수하고 있음을 확인했습니다 그리고 계속해서 거래를 지속할 것이라고 밝혔습니다. 회사는 부정적인 시장 역학을 생성하려는 그러한 잘못된 주장에 맞서기 위해 조치를 취할 것이라고 알려주었습니다.
TC BioPharm (NASDAQ: TCBP) a officiellement démenti de fausses affirmations sur les réseaux sociaux concernant un éventuel retrait de Nasdaq. L'entreprise, qui développe des thérapies par cellules T gamma-delta allogéniques, a abordé des rumeurs provenant d'un post sur les réseaux sociaux, maintenant supprimé, qui affirmait à tort que la société avait déposé un avis 8-K pour se retirer. TC BioPharm a confirmé qu'elle reste pleinement conforme à toutes les exigences de cotation de Nasdaq et continuera à coter sur la bourse. La société a indiqué qu'elle prendra des mesures pour se défendre contre de telles allégations trompeuses visant à créer des dynamiques négatives sur le marché.
TC BioPharm (NASDAQ: TCBP) hat offiziell falsche Social-Media-Aussagen über eine mögliche Delistung von Nasdaq zurückgewiesen. Das Unternehmen, das allogene gamma-delta T-Zell-Therapien entwickelt, ging auf Gerüchte aus einem mittlerweile gelöschten Social-Media-Post ein, der fälschlicherweise behauptete, das Unternehmen habe eine 8-K-Anzeige zur Delistung eingereicht. TC BioPharm bestätigte, dass es weiterhin vollumfänglich alle Nasdaq-Listing-Anforderungen erfüllt und auf der Börse weiter handeln wird. Das Unternehmen kündigte an, Maßnahmen zu ergreifen, um sich gegen solche irreführenden Behauptungen zu verteidigen, die darauf abzielen, negative Marktdynamiken zu schaffen.
- Company confirms full compliance with Nasdaq listing requirements
- Company maintains its Nasdaq listing status
- Company facing targeted misinformation affecting market perception
Insights
This response to misinformation represents a critical defensive move by TC BioPharm to protect shareholder value and market confidence. The company's swift and direct refutation of false delisting claims demonstrates proper corporate governance and transparency. The mention of potential legal action against market manipulation attempts shows the company is taking a strong stance against malicious actors. While the immediate stock impact may be , this proactive communication helps maintain market integrity and protects against reputational damage.
The company's explicit statement of Nasdaq compliance and commitment to defend against market manipulation attempts indicates a well-prepared management team following proper SEC disclosure protocols. This type of clear communication is essential for maintaining investor confidence in micro-cap biotech companies.
- TC BioPharm remains compliant with all Nasdaq listing requirements and will continue trading on the exchange
The since deleted rumor stated that the company had filed an 8-K Notice to "Delist" from the Nasdaq and would transfer trading to a different exchange. TC BioPharm reiterated that there is no truth to this remark and that TC BioPharm remains in compliance with all Nasdaq listing requirements. The Company will look to take action to defend itself from these types of these attacks which are perpetrated in an effort to create negative market dynamics. If you have any additional questions, please reach out to the company directly at ir@tcbiopharm.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company's intent or ability to affect any budget savings or execute on any M&A or capital raising strategy. These statements are based on management's current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties, and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For other important factors that could cause actual results to differ materially from the forward-looking statements in this Current Report on Form 8-K, please see the risks and uncertainties identified under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed with the SEC, all of which is available on the Company's Investor Relations website at www.tcbiopharm.com and on the SEC website at www.sec.gov. All forward-looking statements reflect the Company's beliefs and assumptions only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial in treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.
View original content to download multimedia:https://www.prnewswire.com/news-releases/tcbp-responds-to-false-social-media-claim-302287336.html
SOURCE TC BioPharm
FAQ
Is TC BioPharm (TCBP) being delisted from Nasdaq?
Did TC BioPharm (TCBP) file an 8-K Notice to delist from Nasdaq?
What actions is TC BioPharm (TCBP) taking regarding false delisting claims?
